Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

ImmunoCellular Therapeutics (IMUC.OB) to present at 2nd World Cancer Vaccines Summit

IMUC.OB’s President and CEO Manish Singh PhD will present at the 2nd World Cancer Vaccines Summit at the Radisson Hotel in Boston, MA on Thursday, June 23rd at 2:00 pm.
  • The presentation titled, “Multiple Antigen Vaccines for Glioblastoma” will feature ICT-107, IMUC.OB’s dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

The Bottom Line: The presentation will describe ICT-107′s targeting of multiple antigens present on cancer stem cells and daughter cells, the significant improvements observed in progression free and overall survival data following the phase I trial of ICT-107 in newly diagnosed GBM patients, and the multicenter phase II trial currently underway. The Summit brings together leading executives from all major CROs, oncology pharmaceuticals, cancer vaccine biotechs and investigators in the field. Reiterating, IMUC.OB expanded its Phase II trial of ICT-107 from up to 15 clinical centers to 20 or more. ICT-107 is a dendritic cell based cancer vaccine candidate for the treatment of GBM. The P2 trial of ICT-107 is a double-blind, placebo-controlled, 2:1 randomized study designed to evaluate the safety and efficacy of ICT-107 in patients with newly diagnosed GBM. The study is currently enrolling patients at medical institutions …